Literature DB >> 8882605

Characterization of a 5-HT1B receptor on CHO cells: functional responses in the absence of radioligand binding.

H Giles1, S J Lansdell, M L Bolofo, H L Wilson, G R Martin.   

Abstract

1. Chinese hamster ovary (CHO) cells have been reported to be devoid of 5-HT receptors and have frequently been used as hosts for the expression of cloned 5-HT receptors. Unexpectedly, 5-HT was found to induce profound inhibition of forskolin-stimulated cyclic AMP production in these cells and the aim of this study was to classify the 5-HT receptor involved. 2. In CHO(dhfr-) cells 5-HT was a potent agonist and caused 80-100% inhibition of forskolin stimulated cyclic AMP production. A study using several 5-HT1 receptor agonists revealed the following potencies (p[A50]): RU24969 (9.09 +/- 0.17) > 5-carboxamidotryptamine (8.86 +/- 0.20) > 5-HT (8.07 +/- 0.05) > CP-93,129 (7.74 +/- 0.10) > sumatriptan (5.93 +/- 0.04). All five agonists achieved a similar maximum effect. Irreversible receptor alkylation studies yielded a pKA estimate of 7.04 +/- 0.34 for 5-HT. 3. The 5-HT1A/1B antagonist, (+/-)-cyanopindolol (4-100 nM), caused parallel rightward shifts of the 5-HT concentration-effect curve with no change in asymptote. Schild analysis yielded a pKB estimate of 8.69 +/- 0.09 (Schild slope 1.13 +/- 0.10). (+/-)-Cyanopindolol actually behaved as a partial agonist with an intrinsic activity of 0.2-0.5 and a p[A50] of 8.55. 4. 5-HT (0.01-10 microM) also elicited a concentration-dependent increase in intracellular [Ca2+] in CHO(dhfr-) cells thus demonstrating that dual coupling is not a phenomenon restricted to systems in which there is overexpression of transfected receptors. 5. This agonist and antagonist profile is consistent with the presence of a 5-HT1B receptor. 8-OH-DPAT (1 microM) and renzapride (3 microM) were without effect on forskolin-stimulated cyclic AMP production and ketanserin (0.3 microM) did not antagonize the inhibition produced by 5-HT, thus excluding the involvement of 5-HT1A, 5-HT4, and 5-HT2 receptors. 6. The possibility that expression of a 5-HT1B receptor was associated with the dhfr- mutation was excluded since RU24969, 5-HT and CP-93,129 were also potent agonists in unmutated, CHO-K1 cells: p[A50] 9.03 +/- 0.03, 8.34 +/- 0.05, 7.69 +/- 0.07 respectively, and (+/-)-cyanopindolol (0.1 microM) shifted the 5-HT curve to the right and yielded a pA2 estimate of 8.70 +/- 0.06. 7. Little or no specific binding of [3H]-5-HT (0.1-200 nM) or of the high affinity ligand [125I]-iodocyanopindolol (0.01-3 nM) to CHO(dhfr-) cell membranes could be detected. 5-HT also failed to elicit any increase in the binding of [35S]-GTP gamma S to CHO membranes. 8. In conclusion, cultured CHO cells express 5-HT1B receptors which are negatively coupled to adenylyl cyclase and positively coupled to increases in intracellular calcium. The absence of radioligand binding was unexpected in view of the high potency of 5-HT and the partial agonist activity of the normally 'silent' competitive antagonist, (+/-)-cyanopindolol. This implies very efficient receptor-effector coupling of a low density of 5-HT1B receptors. Clearly, the absence of detectable radioligand binding cannot be assumed to mean the absence of receptors capable of eliciting a significant functional response.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8882605      PMCID: PMC1909806          DOI: 10.1111/j.1476-5381.1996.tb16705.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  25 in total

1.  Characterization of the 5-HT1B recognition site in rat brain: binding studies with (-)[125I]iodocyanopindolol.

Authors:  D Hoyer; G Engel; H O Kalkman
Journal:  Eur J Pharmacol       Date:  1985-11-26       Impact factor: 4.432

2.  Operational models of pharmacological agonism.

Authors:  J W Black; P Leff
Journal:  Proc R Soc Lond B Biol Sci       Date:  1983-12-22

3.  Mouse 5HT1B serotonin receptor: cloning, functional expression, and localization in motor control centers.

Authors:  L Maroteaux; F Saudou; N Amlaiky; U Boschert; J L Plassat; R Hen
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

4.  (-)-Propranolol and (+/-)-cyanopindolol are mixed agonists-antagonists at serotonin autoreceptors in the hippocampus of the rat brain.

Authors:  G Maura; M Ulivi; M Raiteri
Journal:  Neuropharmacology       Date:  1987-07       Impact factor: 5.250

5.  High-level stable expression of recombinant 5-HT1A 5-hydroxytryptamine receptors in Chinese hamster ovary cells.

Authors:  A Newman-Tancredi; R Wootton; P G Strange
Journal:  Biochem J       Date:  1992-08-01       Impact factor: 3.857

6.  Studies on the mechanism of 5-HT1 receptor-induced smooth muscle contraction in dog saphenous vein.

Authors:  M J Sumner; W Feniuk; J D McCormick; P P Humphrey
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

7.  The rat 5-hydroxytryptamine1B receptor is the species homologue of the human 5-hydroxytryptamine1D beta receptor.

Authors:  N Adham; P Romanienko; P Hartig; R L Weinshank; T Branchek
Journal:  Mol Pharmacol       Date:  1992-01       Impact factor: 4.436

8.  Protein kinase C induces phosphorylation and desensitization of the human 5-HT1A receptor.

Authors:  J R Raymond
Journal:  J Biol Chem       Date:  1991-08-05       Impact factor: 5.157

9.  Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity.

Authors:  G Urlaub; L A Chasin
Journal:  Proc Natl Acad Sci U S A       Date:  1980-07       Impact factor: 11.205

10.  Molecular cloning and characterization of a rat brain cDNA encoding a 5-hydroxytryptamine1B receptor.

Authors:  M M Voigt; D J Laurie; P H Seeburg; A Bach
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

View more
  9 in total

1.  Involvement of 5-HT1B receptors in collar-induced hypersensitivity to 5-hydroxytryptamine of the rabbit carotid artery.

Authors:  I S Geerts; K E Matthys; A G Herman; H Bult
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

2.  Factors influencing biased agonism in recombinant cells expressing the human α1A -adrenoceptor.

Authors:  Edilson Dantas da Silva Junior; Masaaki Sato; Jon Merlin; Natalie Broxton; Dana S Hutchinson; Sabatino Ventura; Bronwyn A Evans; Roger J Summers
Journal:  Br J Pharmacol       Date:  2017-06-10       Impact factor: 8.739

3.  5-Hydroxytryptamine 5-HT1B receptors inhibiting cyclic AMP accumulation in rat renal mesangial cells.

Authors:  P Schoeffter; J Pfeilschifter; I Bobirnac
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-01       Impact factor: 3.000

4.  Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells.

Authors:  R H Porter; K R Benwell; H Lamb; C S Malcolm; N H Allen; D F Revell; D R Adams; M J Sheardown
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

5.  RNA-editing of the 5-HT(2C) receptor alters agonist-receptor-effector coupling specificity.

Authors:  K A Berg; J D Cropper; C M Niswender; E Sanders-Bush; R B Emeson; W P Clarke
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

6.  Amphioxus expresses both vertebrate-type and invertebrate-type dopamine D(1) receptors.

Authors:  Chloe Burman; Peter D Evans
Journal:  Invert Neurosci       Date:  2010-11-27

7.  Vasopressin/serotonin interactions in the anterior hypothalamus control aggressive behavior in golden hamsters.

Authors:  C F Ferris; R H Melloni; G Koppel; K W Perry; R W Fuller; Y Delville
Journal:  J Neurosci       Date:  1997-06-01       Impact factor: 6.167

8.  5-Hydroxytryptamine 5-HT1D receptors mediating inhibition of cyclic AMP accumulation in Madin-Darby canine kidney (MDCK) cells.

Authors:  P Schoeffter; I Bobirnac
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-09       Impact factor: 3.000

9.  Dissecting the roles of β-arrestin2 and GSK-3 signaling in 5-HT1BR-mediated perseverative behavior and prepulse inhibition deficits in mice.

Authors:  Summer L Thompson; Stephanie C Dulawa
Journal:  PLoS One       Date:  2019-02-05       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.